Profile data is unavailable for this security.
About the company
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
- Revenue in USD (TTM)0.00
- Net income in USD-37.82m
- Incorporated2016
- Employees14.00
- LocationUnicycive Therapeutics Inc4300 El Camino Real, Suite 210LOS ALTOS 94022United StatesUSA
- Phone+1 (650) 384-0642
- Fax+1 (302) 655-5049
- Websitehttps://unicycive.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspira Women's Health Inc | 8.99m | -14.74m | 30.75m | 64.00 | -- | -- | -- | 3.42 | -1.33 | -1.33 | 0.8698 | -0.1104 | 0.9637 | 13.76 | 5.83 | 140,484.40 | -158.00 | -110.58 | -395.41 | -151.88 | 58.84 | 45.23 | -163.95 | -334.08 | 1.11 | -- | 3.10 | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 32.00m | 1.00 | -- | 0.1787 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Apollomics Inc | 0.00 | -388.09m | 32.38m | -- | -- | 0.4788 | -- | -- | -4.34 | -4.34 | 0.00 | 0.6225 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,391.69 | 0.012 | -- | -- | -- | -154.03 | -- | -- | -- |
| IGC Pharma Inc | 1.22m | -14.15m | 32.41m | 61.00 | -- | 3.43 | -- | 26.65 | -0.2479 | -0.2479 | 0.0217 | 0.142 | 0.0776 | 0.2084 | 7.09 | 19,934.43 | -90.30 | -33.35 | -100.90 | -35.84 | 51.40 | 8.74 | -1,163.24 | -410.26 | 0.8564 | -- | 0.0153 | -- | 129.47 | -16.11 | 23.38 | -- | 25.28 | -- |
| Goldenwell Biotech Inc | 1.08k | -114.27k | 32.42m | -- | -- | 603.21 | -- | 30,020.83 | -0.0012 | -0.0012 | 0.00001 | 0.0005 | 0.0052 | 0.0035 | -- | -- | -54.62 | -- | -54.97 | -- | 43.52 | -- | -10,580.56 | -- | 20.18 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -37.82m | 33.09m | 14.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | 0.5779 | 0.00 | -- | -- | 0.00 | -92.81 | -218.20 | -221.58 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| ImmuCell Corp | 21.28m | -3.90m | 33.20m | 74.00 | -- | 1.34 | -- | 1.56 | -0.5030 | -0.5030 | 2.75 | 3.18 | 0.494 | 2.29 | 9.03 | 269,401.50 | -9.05 | -5.16 | -9.97 | -5.53 | 27.55 | 40.04 | -18.31 | -12.64 | 1.00 | -8.14 | 0.3204 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Nuo Therapeutics Inc | 782.01k | -3.02m | 33.83m | -- | -- | 99.50 | -- | 43.26 | -0.071 | -0.071 | 0.0183 | 0.0075 | 0.4516 | 0.7856 | 4.30 | -- | -174.64 | -116.16 | -294.62 | -354.84 | 78.74 | 70.02 | -386.76 | -854.53 | 1.01 | -1,418.93 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -15.53m | 34.10m | 29.00 | -- | -- | -- | -- | -0.3227 | -0.3227 | 0.00 | -0.0811 | 0.00 | -- | -- | 0.00 | -276.90 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| Rapid Micro Biosystems Inc | 23.10m | -51.90m | 34.29m | 193.00 | -- | 0.3231 | -- | 1.48 | -1.20 | -1.20 | 0.5355 | 2.48 | 0.1535 | 1.37 | 4.34 | 119,663.20 | -34.49 | -- | -38.20 | -- | -22.59 | -- | -224.73 | -- | 5.62 | -- | 0.0028 | -- | 31.44 | -- | 13.71 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -2.16m | 34.44m | -- | -- | 3.31 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
| Marker Therapeutics Inc | 3.32m | -12.21m | 34.52m | 8.00 | -- | 2.92 | -- | 10.39 | -1.38 | -0.636 | 0.3751 | 1.32 | 0.158 | -- | 1.69 | 415,107.50 | -58.12 | -53.74 | -70.75 | -62.25 | -- | -- | -367.79 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -11.89m | 34.93m | 6.00 | -- | 453.00 | -- | -- | -0.8292 | -0.8292 | 0.00 | 0.0041 | 0.00 | -- | -- | 0.00 | -298.08 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 35.50m | 163.00 | -- | 0.174 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Cara Therapeutics Inc | 16.94m | -122.54m | 35.51m | 55.00 | -- | 1.19 | -- | 2.10 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
Data as of May 31 2024. Currency figures normalised to Unicycive Therapeutics Inc's reporting currency: US Dollar USD
50.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Mar 2024 | 3.61m | 10.39% |
| RA Capital Management LPas of 31 Mar 2024 | 3.47m | 9.99% |
| Logos Global Management LPas of 31 Mar 2024 | 3.47m | 9.98% |
| Nantahala Capital Management LLCas of 31 Mar 2024 | 3.34m | 9.60% |
| Rosalind Advisors, Inc.as of 31 Mar 2024 | 1.88m | 5.41% |
| Monashee Investment Management LLCas of 31 Mar 2024 | 1.00m | 2.88% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 339.86k | 0.98% |
| Geode Capital Management LLCas of 31 Mar 2024 | 253.19k | 0.73% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 93.34k | 0.27% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 92.86k | 0.27% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
